1 Preface
1.Table of Contents
1.2 Abbreviations
1.3 Related Reports

2 Executive Summary
2.1 Key Findings
2.2 KOL Insights on Competitive Landscape for Gene Therapy for Neurology Indications

3 Overview - Gene Therapy in Neurology
3.1 Objectives of Gene Therapy
3.2 Gene Therapy Versus Conventiol Therapies
3.3 Optimization of Gene Expression
3.4 Gene Transfer Methods and Vectors Used for Gene Therapy
3.5 Classifications of Gene Therapy
3.6 Sources

4 Gene Therapy in the 8MM
4.1 Global Regulatory Agencies’ Definitions of Gene Therapy
4.2 Gene Therapy in the US
4.3 Gene Therapy in the EU
4.4 Gene Therapy in Japan
4.5 Gene Therapy in Chi
4.6 Currently Marketed Gene Therapies in Neurology
4.7 Sources


5 Pipeline Assessment in the 8MM
5.1 Pipeline Overview
5.2 Pipeline Products - Phase III
5.3 Pipeline Products - Phase II
5.4 Orchard Therapeutics’ OTL-200
5.5 Biogen’s Tofersen sodium
5.6 Roche’s RG-6042
5.7 Sylentis’ Tivanisiran
5.8 ViroMed’s Doperminogene Seltoplasmid
5.9 Sources

6 Clinical Trials Mapping and Design
6.1 Clinical Trial Mapping for all Pipeline Products by Phase, by Sponsor, and by Location
6.2 Clinical Trial Mapping for all Pipeline Products by Status and by Indication
6.3 Clinical Trial Mapping by Phase and Indication for Phase III Therapies
6.4 Clinical Trial Mapping by Phase for Phase II Therapies
6.5 Clinical Trial Duration by Indication for Phase III Therapies (By Types of Molecules)
6.6 Clinical Trial Duration by Indication for Phase II Therapies (By Types of Molecules)
6.7 Ongoing Clinical Development of Phase III Gene Therapies

7 Unmet Needs, Barriers, and Key Company Strategies
7.1 Unmet Needs Within Gene Therapy for CNS Indications
7.2 Challenges and Other Factors to Consider During Different Stages of Product Development
7.3 Key Company Strategies: Acquisitions
7.4 Key Company Strategies: Strategic Partnerships
7.5 Sources

8 Payer Perspective on Gene Therapies in Neurology
8.1 Current Neurology Space
8.2 Challenges Associated with Reimbursement of Novel Gene Therapies
8.3 Cost of Gene Therapies
8.4 Strategies to Tackle the Cost of Gene Therapies
8.5 Innovative Reimbursement Models and Clinical Comparators

9 Market Outlook
9.1 Phase III Gene Therapy Pipeline for Neurology
9.2 Key Launch Dates for Phase III Gene Therapy Pipeline Products

10 Appendix
10.1 Methodology
10.2 Primary Research
10.3 About the Authors
10.4 About GlobalData
10.5 Contact Us
10.6 Disclaimer